对于败血症引起的心肌功能障碍的Levosimendan:朋友还是敌人?
Xinxin Du1,2, Fang Xiong3, Yafei Hou4
1Cardiac Intensive Care Center, Zhongshan Hospital, Fudan University, Shanghai, China.
Frontiers in cardiovascular medicine
|January 23, 2025
概括
莱沃西门丹提供了一种新的治疗败血症引起的心肌功能障碍 (SIMD) 的方法,其作用独立于甲基醇胺. 本综述探讨了其机制和改善SIMD治疗疗效的潜力.
科学领域:
- 心脏病学 心脏病学
- 关键护理医学 关键护理医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 败血症引起的心肌功能障碍 (SIMD) 是一种可逆的疾病,影响心脏输出.
- 像多布他胺和上腺素这样的常规内类药物在治疗SIMD方面表现出有限的疗效.
- 莱沃西门丹 (Levosimendan) 介绍了一种新型的,不依赖于甲基胺的SIMD.的无otropic剂.
研究的目的:
- 审查levosimendan在SIMD中的治疗机制.
- 探索最近关于提高levosimendan对SIMD的疗效的研究.
- 分析levosimendan在SIMD治疗中的潜力和局限性.
主要方法:
- 对治疗机制的文献综述.
- 对最近关于levosimendan疗效的研究进行分析.
- 评估临床试验数据和应用潜力.
主要成果:
- 莱沃西门丹独特的机制为传统的异能菌提供了替代品.
- 不一致的研究结果突出了围绕levosimendan在SIMD中的使用的争议.
- 需要进一步的研究来优化levosimendan的应用和疗效.
结论:
- 由于其独特的机制,Levosimendan在治疗SIMD方面表现有前途.
- 优化levosimendan的使用需要解决当前的不一致性和争议.
- 未来的临床试验应该专注于提炼levosimendan在SIMD中的应用.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
510
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
376
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
01:22Heart Failure Drugs: β-Blockers
314
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
895
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
895
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
706
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
706